Friday, September 16, 2016

CHMP Recommends Approval of Lilly's Olaratumab, in Combination with Doxorubicin, for Advanced Soft Tissue Sarcoma (NYSE:LLY)

Positive Opinion is the First Global Regulatory Step Towards Approval for Olaratumab



CHMP Recommends Approval of Lilly's Olaratumab, in Combination with Doxorubicin, for Advanced Soft Tissue Sarcoma (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.